A股午間公告——景峯醫藥、碩貝德、紅日藥業
格隆匯8月16日丨景峯醫藥(000908.SZ):全資子公司上海景峯製藥近日收到上海市藥監局核准簽發的藥品GMP證書,認證範圍為原料藥玻璃酸鈉。碩貝德(300322.SZ):公司董事兼總經理温巧夫8月14-15日通過大宗交易合計減持公司股份290萬股,佔總股本的0.713%。紅日藥業(300026.SZ):複方電解質注射液(Ⅱ)近日收到國家藥監局下發的藥品註冊批件,該品種用於治療伴隨或預期出現酸中毒的等滲性脱水,補充細胞外液的丟失。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.